Current Report Filing (8-k)
2023年2月25日 - 6:07AM
Edgar (US Regulatory)
0001106644
false
CN
0001106644
2023-02-24
2023-02-24
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported): February
24, 2023
CHINA PHARMA HOLDINGS, INC.
(Exact name of Registrant as specified in charter)
Nevada |
|
001-34471 |
|
73-1564807 |
(State or other jurisdiction |
|
(Commission File No.) |
|
(IRS Employer |
of Incorporation) |
|
|
|
Identification No.) |
Second Floor, No. 17, Jinpan Road
Haikou, Hainan Province, China |
|
570216 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrant's telephone number, including area code:
+86 898-6681-1730 (China)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ | | Written communications pursuant to Rule 425 under the Securities Act (17CFR230.425) |
☐ | | Soliciting material pursuant to Rule14a-12 under the Exchange Act (17CFR240.14a-12) |
☐ | | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR240.14d-2(b)) |
☐ | | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of
the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
Common Stock |
|
CPHI |
|
NYSE American |
Indicate by check mark whether the registrant is an
emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark
if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD Disclosure
On
February 24, 2023, China Pharma Holdings, Inc. issued a press release, included herewith as Exhibit 99.1, announcing that it expects to
implement a 1-for-10 reverse stock split effective Monday, March 6, 2023, with trading to begin on a split-adjusted basis at
the market open on that day.
The
information disclosed under this Item 7.01, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed”
for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be deemed incorporated by reference into any filing
made under the Securities Act of 1933, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Dated: February
24, 2023
|
CHINA PHARMA HOLDINGS, INC. |
|
|
|
By: |
/s/ Zhilin Li |
|
Name:
Title: |
Zhilin Li
President and Chief Executive Officer |
China Pharma (AMEX:CPHI)
過去 株価チャート
から 8 2024 まで 9 2024
China Pharma (AMEX:CPHI)
過去 株価チャート
から 9 2023 まで 9 2024